

17TH SEPTEMBER 2020

The Emerging Immunotherapies in Cancer - II edition, Barcelona, Spain, 17/09/2020 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 4 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.





9.30 h	Welcome	Leticia De Mattos, IrsiCaixa Research
		Institute, Barcelona
9.40 h	Opening lecture: immunotherapy goes local	Ignacio Melero, University of Navarra
	5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 -	Clinic, Navarra
CHAIR: Leticia De Mattos, IrsiCaixa		
TABLE I: Novel cancer immunotherapy approaches and biomarkers		
		Research Institute, Barcelona
10.10 h	Immuno-oncology today in the clinics and in the context of	Caroline Robert, Institut Gustave
	other therapy	Roussy, Paris, France
	Update on Immunotherapy and Combinations in Urothelial	
10.30 h	Malignancies	Joaquim Bellmunt, Harvard Medical School, Boston, USA
	ividiigitaticies	Jenoor, Boston, OJA
10.50 h	Overall discussion	
11: 10 h	BREAK	
CHAIR: Ramon Alemany, Catalan		
TABLE II: Co	mputation biology meets personalized immunotherapy	Institute of Oncology – IDIBELL,
	, , , , , , , , , , , , , , , , , , , ,	Barcelona
	Computational biology: new trends to personalized	Francesco Finatalla Madizinischa
11:40 h	immunotherapy of cancer	Francesca Finotello, Medizinische Universität Innsbruck, Austria
	• •	•
12.00 h	Neoantigens cancer vaccines to shape the immune system in the clinics	Leticia De Mattos, IrsiCaixa Research
	the clinics	Institute, Barcelona
12.20 h	New data on CAR-T cell therapy	Manel Juan, Hospital Clínic de Barcelona
	Overall discussion	
12.40 h	Overall discussion	
12.40 h 13.00 h	Overall discussion LUNCH	
		CHAID: Development Cleated InciCoing
13.00 h		CHAIR: Bonaventura Clotet, IrsiCaixa
13.00 h	LUNCH	CHAIR: Bonaventura Clotet, IrsiCaixa Research Institute. Barcelona
13.00 h TABLE III: N	LUNCH ew perspectives: virus and cancer	
13.00 h	LUNCH	Research Institute. Barcelona
13.00 h TABLE III: N	LUNCH ew perspectives: virus and cancer	Research Institute. Barcelona Ramon Alemany, Catalan Institute of Oncology – IDIBELL, Barcelona Rafael Rosell, Instituto Oncológico Dr.
13.00 h TABLE III: N	EUNCH ew perspectives: virus and cancer Role of oncolytic viruses for cancer treatment	Research Institute. Barcelona Ramon Alemany, Catalan Institute of Oncology – IDIBELL, Barcelona
13.00 h TABLE III: N	EUNCH ew perspectives: virus and cancer Role of oncolytic viruses for cancer treatment Lessons learnt from Durvast trial: novel immunoterapy approaches for cancer patients When immunotherapy should be considered as	Research Institute. Barcelona Ramon Alemany, Catalan Institute of Oncology – IDIBELL, Barcelona Rafael Rosell, Instituto Oncológico Dr. Rosell, Barcelona
13.00 h TABLE III: N	Ew perspectives: virus and cancer Role of oncolytic viruses for cancer treatment Lessons learnt from Durvast trial: novel immunoterapy approaches for cancer patients When immunotherapy should be considered as a treatment option for patients and when it	Research Institute. Barcelona Ramon Alemany, Catalan Institute of Oncology – IDIBELL, Barcelona Rafael Rosell, Instituto Oncológico Dr. Rosell, Barcelona Mariano Provencio, Hospital Puerta de
13.00 h TABLE III: N 14.00 h	Role of oncolytic viruses for cancer treatment Lessons learnt from Durvast trial: novel immunoterapy approaches for cancer patients When immunotherapy should be considered as a treatment option for patients and when it should not	Research Institute. Barcelona Ramon Alemany, Catalan Institute of Oncology – IDIBELL, Barcelona Rafael Rosell, Instituto Oncológico Dr. Rosell, Barcelona
13.00 h TABLE III: N 14.00 h	Role of oncolytic viruses for cancer treatment Lessons learnt from Durvast trial: novel immunoterapy approaches for cancer patients Lessons learnt in the era of COVID-19 infection in melanoma natients:	Ramon Alemany, Catalan Institute of Oncology – IDIBELL, Barcelona Rafael Rosell, Instituto Oncológico Dr. Rosell, Barcelona Mariano Provencio, Hospital Puerta de Hierro, Madrid
13.00 h TABLE III: N 14.00 h	Role of oncolytic viruses for cancer treatment Lessons learnt from Durvast trial: novel immunoterapy approaches for cancer patients Lessons learnt in the era of COVID-19 COVID-19 LUNCH When immunoterapy should be considered as a treatment option for patients and when it should not COVID-19 infection in melanoma patients: results of the Spanish Melanoma Group	Research Institute. Barcelona Ramon Alemany, Catalan Institute of Oncology – IDIBELL, Barcelona Rafael Rosell, Instituto Oncológico Dr. Rosell, Barcelona Mariano Provencio, Hospital Puerta de
13.00 h TABLE III: N 14.00 h 14.20 h	Role of oncolytic viruses for cancer treatment Lessons learnt from Durvast trial: novel immunoterapy approaches for cancer patients Lessons learnt in the era of COVID-19 infection in melanoma patients:	Ramon Alemany, Catalan Institute of Oncology – IDIBELL, Barcelona Rafael Rosell, Instituto Oncológico Dr. Rosell, Barcelona Mariano Provencio, Hospital Puerta de Hierro, Madrid Maria González Cao, Instituto
13.00 h TABLE III: N 14.00 h 14.20 h 14.40 h	Role of oncolytic viruses for cancer treatment Lessons learnt from Durvast trial: novel immunoterapy approaches for cancer patients Lessons learnt in the era of COVID-19 pandemic COVID-19 infection in melanoma patients: results of the Spanish Melanoma Group register	Ramon Alemany, Catalan Institute of Oncology – IDIBELL, Barcelona Rafael Rosell, Instituto Oncológico Dr. Rosell, Barcelona Mariano Provencio, Hospital Puerta de Hierro, Madrid Maria González Cao, Instituto Oncológico Dr. Rosell, Hospital Dexeus,
13.00 h TABLE III: N 14.00 h 14.20 h	Role of oncolytic viruses for cancer treatment Lessons learnt from Durvast trial: novel immunoterapy approaches for cancer patients Lessons learnt in the era of COVID-19 pandemic COVID-19 pandemic LUNCH When incomparity in the considered as a treatment option for patients and when it should not COVID-19 infection in melanoma patients: results of the Spanish Melanoma Group	Ramon Alemany, Catalan Institute of Oncology – IDIBELL, Barcelona Rafael Rosell, Instituto Oncológico Dr. Rosell, Barcelona Mariano Provencio, Hospital Puerta de Hierro, Madrid Maria González Cao, Instituto Oncológico Dr. Rosell, Hospital Dexeus,
13.00 h TABLE III: N 14.00 h 14.20 h 14.40 h	Role of oncolytic viruses for cancer treatment Lessons learnt from Durvast trial: novel immunoterapy approaches for cancer patients Lessons learnt in the era of COVID-19 pandemic COVID-19 infection in melanoma patients: results of the Spanish Melanoma Group register	Ramon Alemany, Catalan Institute of Oncology – IDIBELL, Barcelona Rafael Rosell, Instituto Oncológico Dr. Rosell, Barcelona Mariano Provencio, Hospital Puerta de Hierro, Madrid Maria González Cao, Instituto Oncológico Dr. Rosell, Hospital Dexeus,
13.00 h TABLE III: N 14.00 h 14.20 h 15.00 h	Role of oncolytic viruses for cancer treatment Lessons learnt from Durvast trial: novel immunoterapy approaches for cancer patients Lessons learnt in the era of COVID-19 pandemic COVID-19 infection in melanoma patients: results of the Spanish Melanoma Group register Closing lecture: Immuno-oncology therapies in the clinic:	Ramon Alemany, Catalan Institute of Oncology – IDIBELL, Barcelona Rafael Rosell, Instituto Oncológico Dr. Rosell, Barcelona Mariano Provencio, Hospital Puerta de Hierro, Madrid Maria González Cao, Instituto Oncológico Dr. Rosell, Hospital Dexeus, Barcelona Antoni Ribas, Jonsson Comprehensive Cancer Center David Geffen School of
13.00 h TABLE III: N 14.00 h 14.20 h 14.40 h	Role of oncolytic viruses for cancer treatment Lessons learnt from Durvast trial: novel immunoterapy approaches for cancer patients Lessons learnt in the era of COVID-19 pandemic COVID-19 pandemic LUNCH When immunoterate in the era of covidence as a treatment option for patients and when it should not covidence in melanoma patients: results of the Spanish Melanoma Group register Overall discussion	Ramon Alemany, Catalan Institute of Oncology – IDIBELL, Barcelona Rafael Rosell, Instituto Oncológico Dr. Rosell, Barcelona Mariano Provencio, Hospital Puerta de Hierro, Madrid Maria González Cao, Instituto Oncológico Dr. Rosell, Hospital Dexeus, Barcelona Antoni Ribas, Jonsson Comprehensive



Organized by



The workshop is possible thanks to the support of



Pfizer Inc.